-DOCSTART- -X- O
Vaccination -X- _ O
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
successful -X- _ O
immunology -X- _ O
applications -X- _ O
that -X- _ O
has -X- _ O
considerably -X- _ O
improved -X- _ O
human -X- _ O
health. -X- _ O
The -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
is -X- _ O
a -X- _ O
new -X- _ O
vaccine -X- _ O
being -X- _ O
developed -X- _ O
since -X- _ O
the -X- _ O
early -X- _ O
1990s. -X- _ O
Although -X- _ O
the -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
is -X- _ O
promising -X- _ O
, -X- _ O
no -X- _ O
human -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
has -X- _ O
been -X- _ O
approved -X- _ O
to -X- _ O
date. -X- _ O
The -X- _ O
main -X- _ O
problem -X- _ O
facing -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
efficacy -X- _ O
is -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
a -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
delivery -X- _ I-Intervention
system. -X- _ I-Intervention
Several -X- _ O
studies -X- _ O
explored -X- _ O
this -X- _ O
limitation. -X- _ O
One -X- _ O
of -X- _ O
the -X- _ O
best -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
delivery -X- _ I-Intervention
systems -X- _ I-Intervention
uses -X- _ O
a -X- _ O
live -X- _ B-Intervention
bacterial -X- _ I-Intervention
vector -X- _ I-Intervention
as -X- _ O
the -X- _ O
carrier. -X- _ O
The -X- _ O
live -X- _ B-Intervention
bacterial -X- _ I-Intervention
vector -X- _ I-Intervention
induces -X- _ O
a -X- _ O
robust -X- _ O
immune -X- _ O
response -X- _ O
due -X- _ O
to -X- _ O
its -X- _ O
natural -X- _ O
characteristics -X- _ O
that -X- _ O
are -X- _ O
recognized -X- _ O
by -X- _ O
the -X- _ O
immune -X- _ O
system. -X- _ O
Moreover -X- _ O
, -X- _ O
the -X- _ O
route -X- _ O
of -X- _ O
administration -X- _ O
used -X- _ O
by -X- _ O
the -X- _ O
live -X- _ B-Intervention
bacterial -X- _ I-Intervention
vector -X- _ I-Intervention
is -X- _ O
through -X- _ O
the -X- _ O
mucosal -X- _ O
route -X- _ O
that -X- _ O
beneficially -X- _ O
induces -X- _ O
both -X- _ O
mucosal -X- _ O
and -X- _ O
systemic -X- _ O
immune -X- _ O
responses. -X- _ O
The -X- _ O
mucosal -X- _ O
route -X- _ O
is -X- _ O
not -X- _ O
invasive -X- _ O
, -X- _ O
making -X- _ O
the -X- _ O
vaccine -X- _ O
easy -X- _ O
to -X- _ O
administer -X- _ O
, -X- _ O
increasing -X- _ O
the -X- _ O
patientâ€™s -X- _ O
acceptance. -X- _ O
Lactic -X- _ O
acid -X- _ O
bacterium -X- _ O
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
promising -X- _ O
bacteria -X- _ O
used -X- _ O
as -X- _ O
a -X- _ O
live -X- _ B-Intervention
bacterial -X- _ I-Intervention
vector. -X- _ I-Intervention
However -X- _ O
, -X- _ O
some -X- _ O
other -X- _ O
attenuated -X- _ O
pathogenic -X- _ O
bacteria -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
Salmonella -X- _ O
spp. -X- _ O
and -X- _ O
Shigella -X- _ O
spp. -X- _ O
, -X- _ O
have -X- _ O
been -X- _ O
used -X- _ O
as -X- _ O
DNA -X- _ B-Intervention
vaccine -X- _ I-Intervention
carriers. -X- _ O
Numerous -X- _ O
studies -X- _ O
showed -X- _ O
that -X- _ O
live -X- _ B-Outcome
bacterial -X- _ I-Outcome
vectors -X- _ I-Outcome
are -X- _ I-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
candidate -X- _ I-Outcome
to -X- _ I-Outcome
deliver -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccines -X- _ I-Outcome
. -X- _ O

